Lytix Biopharma AS – Mandatory notification of trade by Primary Insiders and close associates

Oslo, Norway, 17 December 2024: Reference is made to the stock exchange announcement published by Lytix Biopharma AS ("Lytix" or the "Company") earlier today, on 17 December 2024, regarding the successful completion of a private placement of new shares raising NOK 100 million in gross proceeds, and a retail offering of new shares (together with the new shares in the private placement, the “Offer Shares”) raising NOK 11.3 million in gross proceeds via the PrimaryBid platform. As of this date, the Company has been informed that the following primary insiders and close associates to primary insiders have been allocated a total of 3,226,078 Offer Shares, as further set out in the attached forms. Disclosure regulation: This information is subject to the disclosure requirements pursuant to article 19 of the EU Market Abuse Regulation and section 5-12 of the Norwegian Securities Trading Act. For more information, please contact: Gjest Breistein, CFO +47 952 60 512 gjest.breistein@lytixbiopharma.com Lytix in brief: Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with a highly novel technology based on world leading research in host-defense peptide-derived molecules. Lytix Biopharma’s lead product, LTX-315, is a first-in-class oncolytic molecule representing a new principle to boost anti-cancer immunity. Lytix Biopharma has a pipeline of molecules that can work in many different cancer indications and treatment settings, both as mono- and combination therapy.